Dynamic Augmentation of Left Ventricle and Mitral Valve Function With an Implantable Soft Robotic Device

doi:10.1016/j.jacbts.2019.12.001

JACC: Basic to Translational Science

Volume 5, Issue 3, March 2020, Pages 229-242

https://doi.org/10.1016/j.jacbts.2019.12.001 Get rights and content

Under a Creative Commons license

open access

Highlights

•
LVSD is associated with reduced LV systolic function and geometrical changes.
•
MVR results from LVSD.
•
Current management strategies address LVSD and secondary MVR separately, even in advanced stages of LVSD.
•
We describe an implantable soft robotic device that would provide a new paradigm in supporting patients with coexistence of LVSD and concomitant MVR by dynamically augmenting native LV contraction and supporting the mitral valve apparatus to eliminate the associated MVR.

Summary

Left ventricular failure is strongly associated with secondary mitral valve regurgitation. Implantable soft robotic devices are an emerging technology that enables augmentation of a native function of a target tissue. We demonstrate the ability of a novel soft robotic ventricular assist device to dynamically augment left ventricular contraction, provide native pulsatile flow, simultaneously reshape the mitral valve apparatus, and eliminate the associated regurgitation in an Short-term large animal model of acute left ventricular systolic dysfunction.

Visual Abstract

Key Words

left ventricular systolic dysfunction

mitral valve

secondary mitral regurgitation

soft robotic

Abbreviations and Acronyms

fractional shortening

heart failure

IQR

interquartile range

IVS

interventricular septum

LHF

left heart failure

left ventricular

LVEDP

left ventricular end-diastolic pressure

LVSD

left ventricular systolic dysfunction

mitral valve

MVR

mitral valve regurgitation

right ventricle

SRVAD

soft robotic ventricular assist device

Cited by (0)

: This work was supported in part by the U.S. Department of Defense Congressionally Directed Medical Research Programs Discovery Award W81XWH-15-1-0248 (to Dr. Vasilyev), the Wyss Institute for Biologically Inspired Engineering, and the Harvard John A. Paulson School of Engineering and Applied Sciences. Drs. Payne and Vasilyev were the inventors and are listed on a patent application related to the research presented in this paper submitted on June 24, 2016, application number 62/354,196. Dr. Vasilyev is currently an employee of Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

: The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.